Search Result

Results for "

insulin sensitizer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Insulin Receptor (3) Apoptosis (1) CGRP Receptor (1) Endogenous Metabolite (2) Lactate Dehydrogenase (1) Mitochondrial Metabolism (1) NOD-like Receptor (NLR) (3) Phosphatase (1) PPAR (6) Proton Pump (2) RAR/RXR (1) SHP2 (1) TRP Channel (1)
By Research Areas:	Cancer (6) Endocrinology (2) Inflammation/Immunology (4) Metabolic Disease (15) Neurological Disease (2)

Inhibitors & Agonists

Natural
Products

Targets Recommended: Insulin Receptor IGF-1R

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108523

LG100754 UVI 2112	RAR/RXR	Metabolic Disease
LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR .

HY-111254

GQ-16	PPAR	Metabolic Disease
GQ-16 is a moderate affinity ligand for the ligand-binding domain (LBD) of PPARγ, exhibiting a K_i of 160 nM. GQ-16 is an effective inhibitor of Cdk5-mediated phosphorylation of PPARγ. GQ-16 is a partial agonist of PPARγ with reduced adipogenic actions. GQ-16 promotes insulin Sensitization without weight gain .

HY-100550

MSDC 0160 2 Publications Verification Mitoglitazone; CAY10415	Insulin Receptor Mitochondrial Metabolism	Neurological Disease Endocrinology
MSDC 0160 (Mitoglitazone) is a mitochondrial target of thiazolidinediones (mTOT)-modulating **insulin sensitizer and a modulator of mitochondrial pyruvate carrier (MPC)**. MSDC 0160 is a thiazolidinedione (TZD) with antidiabetic and neuroprotective activities. MSDC 0160 has the potential for Alzheimer′s disease .

HY-164368

GLUT4 activator 2	Others	Metabolic Disease
GLUT4 activator 2 (C59) is an *insulin* sensitizer, which can be used for research of diabetic diseases. GLUT4 activator 2 improves glucose uptake and insulin sensitivity in rodents. GLUT4 activator 2 interacts with Unc119 and Unc119B resulting in increased insulin sensitivity and GLUT4 translocation .

HY-160162

SR 11023	PPAR	Metabolic Disease
SR 11023 is an orally active antagonist of PPARγ, with the IC₅₀ value of 109 nM that plays an important role in diabetic research .

HY-N2177

3-Dehydrotrametenolic acid	Lactate Dehydrogenase Apoptosis	Cancer
3-Dehydrotrametenolic acid, isolated from the sclerotium of Poria cocos, is a lactate dehydrogenase (LDH) inhibitor. 3-Dehydrotrametenolic acid promotes adipocyte differentiation in vitro and acts as an insulin sensitizer in vivo. 3-Dehydrotrametenolic acid induces apoptosis and has anticancer activity .

HY-13682

Mifamurtide 1 Publications Verification MTP-PE; L-MTP-PE; CGP 19835	NOD-like Receptor (NLR)	Inflammation/Immunology Cancer
Mifamurtide (MTP-PE), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide has potential for use in rare disease and osteosarcoma research .

HY-13682B

Mifamurtide sodium 1 Publications Verification MTP-PE sodium; L-MTP-PE sodium; CGP 19835 sodium	NOD-like Receptor (NLR)	Inflammation/Immunology Cancer
Mifamurtide sodium (MTP-PE sodium), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide sodium is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide sodium has potential for use in rare disease and osteosarcoma research .

HY-19176

S-15261	Others	Metabolic Disease
S-15261 is an orally active and potent anti-hyperglycemic agent. S-15261 reduces hepatic glucose production through direct and insulin-sensitizing effects. S-15261 can be used for the research of insulin resistance syndrome .

HY-16421

Ragaglitazar (-)-DRF 2725; NNC 61-0029	PPAR	Metabolic Disease
Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.

HY-108022A

Azemiglitazone potassium MSDC-0602K	Insulin Receptor PPAR	Metabolic Disease
Azemiglitazone potassium (MSDC-0602K), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC₅₀ of 18.25 μM . Azemiglitazone potassium modulates the mitochondrial pyruvate carrier (MPC). Azemiglitazone potassium can be used for the research of fatty liver including dysfunctional lipid metabolism, inflammation, and insulin resistance . Azemiglitazone potassium, an *insulin* sensitizer, improves insulinemia and fatty liver disease in mice, alone and in combination with Liraglutide .

HY-13682A

Mifamurtide sodium hydrate MTP-PE sodium hydrate; L-MTP-PE sodium hydrate; CGP 19835 sodium hydrate	Others	Inflammation/Immunology Cancer
Mifamurtide (sodium hydrate) (MTP-PE (sodium hydrate); L-MTP-PE (sodium hydrate); CGP 19835 (sodium hydrate)) is the sodium hydrate of mifamurtide. Mifamurtide is a nonspecific immunomodulator that acts by stimulating immune responses by activating macrophages and monocytes. Mifamurtide is a specific ligand for NOD2 and is used as an insulin sensitizer and may also be used in osteosarcoma research .

HY-126969

C333H	Others	Metabolic Disease
C333H is a selective PPARγ modulator with insulin-sensitizing and hypoglycemic activities. C333H exhibits similar insulin-sensitizing effects to thiazolidinediones (TZDs) in diabetic mouse models without significantly increasing body weight or adipose tissue weight. C333H increases circulating high molecular weight adiponectin isoform levels in diabetic db/db mice, reduces serine phosphorylation of PPARγ 273 in brown adipose tissue, and selectively modulates the expression of specific PPARγ target genes in adipose tissue. Express. C333H exhibits weak recruitment of co-activators and weak dissociation of co-repressors in vitro. These properties suggest that C333H may be a potential inhibitor of type 2 diabetes .

HY-13682C

Mifamurtide TFA 1 Publications Verification MTP-PE TFA; L-MTP-PE TFA; CGP 19835 TFA	NOD-like Receptor (NLR)	Inflammation/Immunology Cancer
Mifamurtide TFA (MTP-PE TFA), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide TFA is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide TFA has potential for use in rare disease and osteosarcoma research .

HY-147705

PPARγ phosphorylation inhibitor 1	PPAR	Metabolic Disease
PPARγ phosphorylation inhibitor 1 (Compound 10) is a potent PPARγ binder with the IC₅₀ of 24 nM. PPARγ phosphorylation inhibitor 1 inhibits CDK5-mediated phosphorylation of PPARγ Ser273 with the IC₅₀ of 160 nM. PPARγ phosphorylation inhibitor 1 displays negligible PPARγ agonism in a reporter gene assay. Antidiabetic effects .

HY-19960

BCTC 3 Publications Verification	TRP Channel Insulin Receptor CGRP Receptor	Neurological Disease Metabolic Disease Cancer
BCTC is an orally active current inhibitor of vanilloid receptor type 1 (VR1). BCTC is a transient receptor potential cation channel subfamily M member 8 (TRPM8) and transient receptor potential vanilloid 1 (TRPV1) antagonist. BCTC is an insulin sensitizer and secretor. BCTC has anticancer and analgesic effects .

HY-118567

Bis(maltolato)oxovanadium(IV) BMOV	SHP2 Phosphatase	Metabolic Disease
Bis(maltolato)oxovanadium(IV) (BMOV) is a potent, reversible, competitive and orally active pan-PTP (protein tyrosine phosphatases) inhibitor. Bis(maltolato)oxovanadium(IV) inhibits HCPTPA, PTP1B, HPTPβ and SHP2 with IC₅₀s of 126 nM, 109 nM, 26 nM and 201 nM, respectively. Bis(maltolato)oxovanadium(IV) is a potent insulin sensitizer .

HY-100560

Abscisic acid 1 Publications Verification (S)-(+)-Abscisic acid; ABA	Endogenous Metabolite Proton Pump	Metabolic Disease
Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits proton pump (H ⁺-ATPase) and leads to the plasma membrane depolarization in a Ca ²⁺-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome .

HY-112584

JBSNF-000088 3 Publications Verification 6-Methoxynicotinamide	Others	Metabolic Disease
JBSNF-000088 (6-Methoxynicotinamide), a analog of nicotinamide (NA), is a potent and orally active Nicotinamide N-methyltransferase (NNMT) inhibitor with IC₅₀s of 1.8 µM, 2.8 µM, and 5.0 µM for human NNMT, monkey NNMT and mouse NNMT, respectively. JBSNF-000088 inhibits NNMT activity, reduces MNA levels and drives insulin sensitization, glucose modulation and body weight reduction in animal models of metabolic disease .

HY-100560R

Abscisic acid (Standard)	Endogenous Metabolite Proton Pump	Metabolic Disease
Abscisic acid (Standard) is the analytical standard of Abscisic acid. This product is intended for research and analytical applications. Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits proton pump (H+-ATPase) and leads to the plasma membrane depolarization in a Ca2+-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome .

HY-121900

LT175	PPAR	Metabolic Disease Endocrinology
LT175, a dual PPARα/γ ligand, is an orally active partial agonist against PPARγ(hPPARα:EC₅₀=0.22 μm; mPPARα:EC₅₀=0.26 μm; hPPARγ:EC₅₀=0.48 μm). LT175 interacts with PPARγ and affects the recruitment of the coregulators cyclic-AMP response element-binding protein-binding protein and nuclear corepressor 1 (NCoR1). LT175 interacts with PPARγ in a hydrophobic region called “diphenyl pocket”. LT175 has potent insulin-sensitizing effects and reduced adipogenic properties .

3-Dehydrotrametenolic acid	Triterpenes Structural Classification Classification of Application Fields Terpenoids Polyporaceae Source classification Poria cocos Plants Disease Research Fields Cancer	Lactate Dehydrogenase Apoptosis
3-Dehydrotrametenolic acid, isolated from the sclerotium of Poria cocos, is a lactate dehydrogenase (LDH) inhibitor. 3-Dehydrotrametenolic acid promotes adipocyte differentiation in vitro and acts as an insulin sensitizer in vivo. 3-Dehydrotrametenolic acid induces apoptosis and has anticancer activity .

Abscisic acid 1 Publications Verification (S)-(+)-Abscisic acid; ABA	Structural Classification Classification of Application Fields Source classification Metabolic Disease Plants Endogenous metabolite Agricultural Research Microorganisms other families Animals Terpenoids Sesquiterpenes Abscisic acid Phytohormone Disease Research Fields	Endogenous Metabolite Proton Pump
Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits proton pump (H ⁺-ATPase) and leads to the plasma membrane depolarization in a Ca ²⁺-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome .

Abscisic acid (Standard)	Structural Classification Microorganisms other families Animals Terpenoids Sesquiterpenes Source classification Plants Endogenous metabolite	Endogenous Metabolite Proton Pump
Abscisic acid (Standard) is the analytical standard of Abscisic acid. This product is intended for research and analytical applications. Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits proton pump (H+-ATPase) and leads to the plasma membrane depolarization in a Ca2+-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

insulin sensitizer

Inhibitors & Agonists

NaturalProducts

Natural
Products